Arvinas (NASDAQ:ARVN) Issues Earnings Results, Beats Estimates By $0.44 EPS

Arvinas (NASDAQ:ARVN) issued its quarterly earnings results on Tuesday. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.44, Zacks reports. During the same quarter in the prior year, the firm earned ($2.53) EPS.

Arvinas Trading Up 1.5 %

Shares of ARVN opened at $17.95 on Thursday. Arvinas has a 52 week low of $16.61 and a 52 week high of $53.08. The firm’s 50-day simple moving average is $19.18 and its 200 day simple moving average is $23.32.

Wall Street Analyst Weigh In

ARVN has been the topic of a number of recent research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arvinas in a research report on Friday, February 7th. Stifel Nicolaus lowered their price target on Arvinas from $63.00 to $51.00 and set a “buy” rating on the stock in a research report on Wednesday. BTIG Research began coverage on Arvinas in a report on Tuesday, December 10th. They issued a “buy” rating and a $69.00 price objective for the company. Oppenheimer boosted their target price on shares of Arvinas from $40.00 to $45.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, Wedbush reiterated an “outperform” rating and issued a $57.00 price target on shares of Arvinas in a research note on Tuesday. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $59.58.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.